PillRx only · Injection, Solution · Intravenous
Norepinephrine Bitartrate
Norepinephrine Bitartrate
4 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US12 NDCs
4 active makers
4 active makers
UKComing
soon
soon
CAComing
soon
soon
AUComing
soon
soon
EUComing
soon
soon
Medicaid dispensing volumeSDUD · per quarter
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
263
Rx · 2026 Q1
35K
Units dispensed
-63%
Rx vs. year ago
5
Quarters · since 2025 Q1
Who makes it4 active · 0 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Baxter Healthcare Corporation | unknown | 6 | SUPPLYING |
| WG Critical Care, LLC | unknown | 4 | SUPPLYING |
| Avenacy, LLC | unknown | 1 | SUPPLYING |
| Sagent Pharmaceuticals | unknown | 1 | SUPPLYING |
Regulatory & supply eventsFDA · US
Shortages, recalls, and registration changes attached to this drug concept.
- Jan 23, 2024RECALLRecall (Class II): Norepinephrine Bitartrate in 5% Dextrose Injection, 8 mg/ 250 mL (32 mcg/mL), For Intravenous Infusion Only, 250 mL via…
Incorrect product concentration on the overwrap label: The overwrap label incorrectly identified the product strength as 4 mg / 250 mL; however, the primary bag label correctly identified the product strength as 8 mg / 250 mL. — Recalling firm: Baxter Healthcare Corporation — Nationwide in the USA